Abstract
Response to comment on ‘Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial’
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have